ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Ixekizumab"

  • Abstract Number: 1347 • ACR Convergence 2021

    Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement

    Atul Deodhar1, Dafna Gladman2, Rebecca Bolce3, David Sandoval3, So Young Park3, Soyi Liu-Leage4, Peter Nash5 and Denis Poddubnyy6, 1Oregon Health & Science University, Portland, OR, 2Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Eli Lilly and Company, Indianapolis, IN, 4Eli Lilly and Company, Neuilly sur Seine, France, 5Griffith University, Brisbane, Australia, 6Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: Many patients with psoriatic arthritis (PsA) experience back pain and stiffness indicative of axial involvement [1]. The prevalence of axial involvement varies between 25-70%…
  • Abstract Number: 1828 • ACR Convergence 2021

    Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis

    Sergio Schwartzman1, Atul Deodhar2, Bernard Combe3, Ana Accioly4, Andris Kronbergs4, Boris Janos5, Danting Zhu4, David Sandoval Calderon4, Proton Rahman6 and Denis Poddubnyy7, 1Self Employed 72nd Street Medical Associates, Scarsdale, NY, 2Oregon Health & Science University, Portland, OR, 3CHU Montpellier Montpellier University, Montpellier, France, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly, Calgary, AB, Canada, 6Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 7Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A approved for the treatment of psoriasis, psoriatic arthritis (PsA), active ankylosing spondylitis (AS)…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences